Revel Pharmaceuticals, a Kizoo portfolio company, announces an $8.4M seed to develop repair-based approaches to reversing aging
I am proud to have led this $8.2M investment round at Revel Pharmaceuticals, which will help expand Revel’s pipeline for enzymatic repair and crosslink-breakers. These enzyme therapies can reverse the effects of aging, by repairing damage accumulated over time.
Congratulations to Aaron Cravens and the entire team. Starbloom Capital and James Fickel are welcome!
Join the team: forever-healthy.org/careers
San Francisco, CA (U.S.A.), – Revel Pharmaceuticals announced today that the company has raised $8.4M for Seed financing. The round was oversubscribed by Kizoo Technology Capital and Starbloom Capital, two early-stage investors in rejuvenation technologies. Tubus LLC also participated. The funds will help Revel advance its repair-based, enzyme therapy pipeline to the clinic.
Enzymes are used therapeutically today in a few applications. These include wrinkle treatment (Botox), cancer treatment (Asparaginase), or cystic fibrosis therapy (DNase). Revel Pharmaceuticals is reinventing the use of enzymes as therapeutics, by creating repair-based approaches for aging and diseases.
The toxic byproducts from metabolism, which build up on long-lasting collagen proteins that give our bodies their structure, are a major cause of aging. Over time, these toxic byproducts accumulate in the body, causing inflammation, stiffening of tissues, increased blood pressure and kidney damage. They also increase stroke and death risk. Revel is working on designer enzymes that will repair and remove this aging damage.
Source:
https://kizoo.com/news/kizoo-portfolio-company-revel-pharmaceuticals-announces-8-4m-seed-to-develop-repairing-based-approaches-to-reversing-aging/
